New idea for targeting the common cancer protein KRAS
Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented by researchers from the Vanderbilt School of Medicine (home of the Vanderbilt-Ingram Cancer Center) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.